SOURCE: Wall Street Equity Research

Wall Street Equity Research

December 27, 2010 08:10 ET

Professional Research on Soligenix Inc. and Titan Pharmaceuticals Inc. - Government Grants Helping Biotech Companies

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 27, 2010) - www.wallstreetequityresearch.com gives shareholders valuable insight on biotechnology stocks Soligenix Inc. (OTCBB: SNGX) and Titan Pharmaceuticals Inc. (OTCBB: TTNP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

Biotechnology companies are currently bringing new and innovative products to the market, but the journey from idea to realization in the biotech industry is a very long and expensive one. Biotech companies, such as Soligenix Inc. and Titan Pharmaceuticals Inc. have successfully taken advantage of government grants and awards, to keep their labs open while conducting their research and development. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the biotechnology industry in today's economic environment.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports biotechnology industry; traders looking for analyst opinions on Soligenix Inc., Titan Pharmaceuticals Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

Titan Pharmaceuticals is currently in phase three development of an implant that delivers Buprenorphine, a drug that combats opioid addiction. The company has received grants from the National Institutes of Health (NIH) and is also generating royalty revenue from the sale of Fanapt. Traders can have complimentary access to today's complete research report on Titan Pharmaceuticals Inc. by signing up at http://wallstreetequityresearch.com/December272010TitanPharmaceuticalsInc.(TTNP.OB)271210.php.

Soligenix Inc. is another company that has received NIH grants, and is using the money to further their research and development of their drug RiVax. The immunogen is designed to immunize people against the ricin toxin, a deadly toxin that some speculate could be a bio-terror threat. Traders can get direct and free access to today's full report on Soligenix Inc. by signing up at http://wallstreetequityresearch.com/December272010SoligenixInc.(SNGX.OB)271210.php.

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information